Skip to Content
Merck
  • [Experimental therapy in Chinese hamsters and rats infected with larval Echinococcus multilocularis by using mebendazole, albendazole and ivermectin with brief review of chemotherapy of human multilocular echinococcosis].

[Experimental therapy in Chinese hamsters and rats infected with larval Echinococcus multilocularis by using mebendazole, albendazole and ivermectin with brief review of chemotherapy of human multilocular echinococcosis].

[Hokkaido igaku zasshi] The Hokkaido journal of medical science (1987-01-01)
T Inaoka, M Nakao, K Ohnishi, H Kutsumi
ABSTRACT

The effects of the mebendazole, albendazole and ivermectin on secondary multilocular echinococcosis in Chinese hamsters infected with intraperitoneal inoculation of protoscolices and in rats infected with transportal inoculation of protoscolices were investigated. A reduction in weight of the hydatids greater than 95% was recorded in Chinese hamsters intraperitoneally injected with mebendazole suspension. Oral administration of mebendazole moderately inhibited the development of the hydatids. Albendazole was less effective than mebendazole. Ivermectin was ineffective. The treatment with mebendazole of larval E. multilocularis inhibited the growth of the hydatids but it could not completely kill the parasite tissues. The present status of chemotherapy of the human multilocular echinococcosis was briefly discussed.

MATERIALS
Product Number
Brand
Product Description

Mebendazole for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Mebendazole, United States Pharmacopeia (USP) Reference Standard
Mebendazole, European Pharmacopoeia (EP) Reference Standard
Supelco
Mebendazole, VETRANAL®, analytical standard
Supelco
Mebendazole, analytical standard, ≥98% (HPLC)